Baseline epicardial adipose tissue adiponectin levels predict cardiovascular outcomes: A long-term follow-up study

Cytokine

Volumn 60, Issue 3, 2012, Pages 674-680

  Teijeira Fernandez, Elvis ^a   Eiras, Sonia ^a   Salgado Somoza, Antonio ^a   Gonzalez Juanatey, Jose R ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

Adiponectin; Cardiovascular; Epicardial adipose tissue; Leptin; Prognosis

Indexed keywords

ADIPONECTIN; LEPTIN; MESSENGER RNA;

ADIPOSE TISSUE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; EPICARDIAL ADIPOSE TISSUE; FEMALE; HEART FAILURE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SUBCUTANEOUS FAT;

ADIPONECTIN; ADIPOSE TISSUE; AGED; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEPTIN; MALE; PERICARDIUM; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84867983455     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.08.012     Document Type: Article

References (39)

1. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
2. Ouchi N., Kihara S., Arita Y., Nishida M., Matsuyama A., Okamoto Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class a scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063.
3. Yokota T., Oritani K., Takahashi I., Ishikawa J., Matsuyama A., Ouchi N., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96:1723-1732.
4. Berg A.H., Combs T.P., Scherer P.E. Acrp30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002, 13:84-89.
5. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
6. Turer A.T., Scherer P.E. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012, 55:2319-2326.
7. Santaniemi M., Kesaniemi Y.A., Ukkola O. Low plasma adiponectin concentration is an indicator of the metabolic syndrome. Eur J Endocrinol 2006, 155:745-750.
8. Iwashima Y., Katsuya T., Ishikawa K., Ouchi N., Ohishi M., Sugimoto K., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004, 43:1318-1323.
9. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595-1599.
10. Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003, 23:85-89.
11. Kistorp C., Faber J., Galatius S., Gustafsson F., Frystyk J., Flyvbjerg A., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112:1756-1762.
12. Choi K.M., Lee J., Lee K.W., Seo J.A., Oh J.H., Kim S.G., et al. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly koreans. Clin Endocrinol (Oxf) 2004, 61:75-80.
13. Schnabel R., Messow C.M., Lubos E., Espinola-Klein C., Rupprecht H.J., Bickel C., et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the atherogene study. Eur Heart J 2008, 29:649-657.
14. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
15. Dekker J.M., Funahashi T., Nijpels G., Pilz S., Stehouwer C.D., Snijder M.B., et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008, 93:1489-1496.
16. Kistorp C., Faber J., Galatius S., Gustafsson F., Frystyk J., Flyvbjerg A., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112:1756-1762.
17. Forsblom C., Thomas M.C., Moran J., Saraheimo M., Thorn L., Wadén J., et al. Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med 2011, 270:346-355.
18. Sattar N. Adiponectin and raised mortality in type 1 diabetes: any credible explanatory mechanisms?. J Intern Med 2011, 270:339-342.
19. Poehls J., Wassel C.L., Harris T.B., Havel P.J., Swarbrick M.M., Cummings S.R., et al. Association of adiponectin with mortality in older adults: the health, aging, and body composition study. Diabetologia 2009, 52:591-595.
20. Fain J.N., Madan A.K., Hiler M.L., Cheema P., Bahouth S.W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145:2273-2282.
21. Parhami F., Tintut Y., Ballard A., Fogelman A.M., Demer L.L. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001, 88:954-960.
22. van Dielen F.M., Van't Veer C., Schols A.M., Soeters P.B., Buurman W.A., Greve J.W. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord 2001, 25:1759-1766.
23. Wallace A.M., McMahon A.D., Packard C.J., Kelly A., Shepherd J., Gaw A., et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (woscops). Circulation 2001, 104:3052-3056.
24. Sattar N., Wannamethee G., Sarwar N., Chernova J., Lawlor D.A., Kelly A., et al. Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol 2009, 53:167-175.
25. Lieb W., Sullivan L.M., Harris T.B., Roubenoff R., Benjamin E.J., Levy D., et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals. Diabetes Care 2009, 32:612-616.
26. Mazurek T., Zhang L., Zalewski A., Mannion J.D., Diehl J.T., Arafat H., et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003, 108:2460-2466.
27. Teijeira-Fernandez E., Eiras S., Grigorian-Shamagian L., Fernandez A., Adrio B., Gonzalez-Juanatey J.R. Epicardial adipose tissue expression of adiponectin is lower in patients with hypertension. J Hum Hypertens 2008, 22:856-863.
28. Eiras S., Teijeira-Fernandez E., Shamagian L.G., Fernandez A.L., Vazquez-Boquete A., Gonzalez-Juanatey J.R. Extension of coronary artery disease is associated with increased il-6 and decreased adiponectin gene expression in epicardial adipose tissue. Cytokine 2008, 43:174-180.
29. Teijeira-Fernandez E., Eiras S., Grigorian-Shamagian L., Salgado-Somoza A., Martinez-Comendador J.M., Gonzalez-Juanatey J.R. Diabetic and nondiabetic patients express similar adipose tissue adiponectin and leptin levels. Int J Obes (Lond) 2010, 34:1200-1208.
30. Iglesias M.J., Eiras S., Pineiro R., Lopez-Otero D., Gallego R., Fernandez A.L., et al. Gender differences in adiponectin and leptin expression in epicardial and subcutaneous adipose tissue. Findings in patients undergoing cardiac surgery. Rev Esp Cardiol 2006, 59:1252-1260.
31. Liu Y.M., Lacorte J.M., Viguerie N., Poitou C., Pelloux V., Guy-Grand B., et al. Adiponectin gene expression in subcutaneous adipose tissue of obese women in response to short-term very low calorie diet and refeeding. J Clin Endocrinol Metab 2003, 88:5881-5886.
32. Hui X., Lam K.S., Vanhoutte P.M., Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol 2012, 165:574-590.
33. Zhou Y., Wei Y., Wang L., Wang X., Du X., Sun Z., et al. Decreased adiponectin and increased inflammation expression in epicardial adipose tissue in coronary artery disease. Cardiovasc Diabetol 2011, 10:2.
34. Wilk S., Scheibenbogen C., Bauer S., Jenke A., Rother M., Guerreiro M., et al. Adiponectin is a negative regulator of antigen-activated T cells. Eur J Immunol 2011, 41:2323-2332.
35. Raffaghello L., Bianchi G., Pistoia V. Immunosuppressive treatments in acute myocardial infarction and stroke. Curr Pharm Biotechnol 2012, 13:59-67.
36. Teijeira-Fernandez E., Eiras S., Grigorian Shamagian L., Salgado Somoza A., Delgado C., Gonzalez-Juanatey J.R. Lower epicardial adipose tissue adiponectin in patients with metabolic syndrome. Cytokine 2011, 54:185-190.
37. Mangge H., Almer G., Truschnig-Wilders M., Schmidt A., Gasser R., Fuchs D. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem 2010, 17:4511-4520.
38. Kern P.A., Di Gregorio G.B., Lu T., Rassouli N., Ranganathan G. Adiponectin expression from human adipose tissue: Relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003, 52:1779-1785.
39. Iacobellis G., Pistilli D., Gucciardo M., Leonetti F., Miraldi F., Brancaccio G., et al. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine 2005, 29:251-255.